Introduction
============

Treatment with a platinum-based doublet as first-line chemotherapy is the current standard-of-care in patients with non-small cell lung cancer (NSCLC) \[[@b1-crt-2013-266],[@b2-crt-2013-266]\]. Extended first-line chemotherapy with a platinum-based doublet is not recommended as it leads to cumulative toxicities and provides no additional advantage to patients with NSCLC \[[@b1-crt-2013-266],[@b3-crt-2013-266],[@b4-crt-2013-266]\]. The goal of maintenance therapy is to improve progression-free survival (PFS) and overall survival (OS) while maintaining an adequate tolerability profile and quality of life. A well-tolerated, active maintenance treatment may benefit patients who have not progressed during first-line or induction treatment due to prolongation of tumor control. Maintenance therapy in advanced NSCLC, which comprises either continuation of non-platinum chemotherapy (continuation maintenance) or introduction of a new agent (switch maintenance), has been shown to be an effective strategy for improving survival and has become a recommended therapeutic option.

Pemetrexed, a multi-targeted antifolate, acts by disrupting the folate-dependent metabolic processes essential for cell replication \[[@b5-crt-2013-266]\] and is a standard-of-care option in the first-line treatment of nonsquamous NSCLC as a combination therapy with platinum \[[@b6-crt-2013-266]\], as a single agent for second-line therapy \[[@b7-crt-2013-266]\], and as switch maintenance therapy \[[@b8-crt-2013-266]\]. A *post hoc* subgroup analysis of results from a global, phase III trial (JMEN) supports pemetrexed as switch maintenance therapy in East Asian (EA) patients with advanced nonsquamous NSCLC, and was consistent with results from the overall population \[[@b9-crt-2013-266]\].

A recent global, phase III study (PARAMOUNT) demonstrated that pemetrexed continuation maintenance therapy resulted in improved OS and PFS versus placebo, leading to its regulatory approval as a new treatment option for advanced nonsquamous NSCLC \[[@b10-crt-2013-266],[@b11-crt-2013-266]\], and its inclusion in the recent National Comprehensive Cancer Network guidelines for NSCLC \[[@b1-crt-2013-266]\]. However, the majority of patients enrolled in the PARAMOUNT study were Caucasian (94%) and further data are required to validate the efficacy of pemetrexed continuation maintenance therapy in EA patients.

Studies S110 \[[@b12-crt-2013-266]\] and JMII \[[@b13-crt-2013-266]\] were two clinical trials that investigated the efficacy and safety of pemetrexed continuation maintenance therapy in EA patients. The objective of this analysis was to review the efficacy and safety data from these two clinical trials in EA patients to supplement the data from PARAMOUNT on pemetrexed continuation maintenance therapy in patients with nonsquamous NSCLC.

Materials and Methods
=====================

1. Study design
---------------

The study designs for all three studies were reported previously \[[@b10-crt-2013-266],[@b12-crt-2013-266],[@b13-crt-2013-266]\]. Study S110 compared the efficacy and safety of pemetrexed and cisplatin as first-line treatment, followed sequentially by switch maintenance with gefitinib versus continuation maintenance with pemetrexed in patients with locally advanced or metastatic NSCLC in patients from China, Korea, and Taiwan \[[@b12-crt-2013-266]\]. Study JMII evaluated the efficacy and safety of pemetrexed plus carboplatin as induction therapy, followed by pemetrexed as maintenance therapy, in patients from Japan with advanced nonsquamous NSCLC \[[@b13-crt-2013-266]\]. PARAMOUNT was a global study conducted in patients with advanced nonsquamous NSCLC to compare the efficacy and safety of pemetrexed plus best supportive care (BSC) with placebo plus BSC as maintenance therapy following induction treatment with pemetrexed plus cisplatin combination chemotherapy \[[@b10-crt-2013-266]\].

2. Treatment plan
-----------------

The treatment regimens for all three studies were reported previously \[[@b10-crt-2013-266],[@b12-crt-2013-266],[@b13-crt-2013-266]\]. [Table 1](#t1-crt-2013-266){ref-type="table"} shows details of the study designs, the number of patients enrolled and randomized, and the number of patients treated during the induction and maintenance phases. Details of the drug manufacturers were published previously \[[@b10-crt-2013-266],[@b12-crt-2013-266],[@b13-crt-2013-266]\] and, in all of these studies, pemetrexed was administered intravenously (500 mg/m^2^) on day 1 of a 3-week cycle as described in the pemetrexed label. All patients treated with pemetrexed received dexamethasone, folic acid, and vitamin B~12~, except for the Japanese patients who did not receive dexamethasone as it was not per the pemetrexed label in Japan.

3. Eligibility criteria
-----------------------

Detailed eligibility criteria were reported previously \[[@b10-crt-2013-266],[@b12-crt-2013-266],[@b13-crt-2013-266]\]. The key eligibility criteria are presented in [Table 2](#t2-crt-2013-266){ref-type="table"}. These studies were conducted in accordance with the ethical principles originating in the Declaration of Helsinki, good clinical practices, and all applicable laws and regulations. The institutional review board at each site approved the study, and all subjects provided written informed consent before undergoing any study procedure.

4. Efficacy and safety assessments
----------------------------------

PFS was the primary endpoint for all three studies, the definition of which was based on each study design, as previously reported \[[@b10-crt-2013-266],[@b12-crt-2013-266],[@b13-crt-2013-266]\]. To assess PFS for the maintenance period in studies JMII and S110, PFS of the induction period was subtracted from PFS for the entire period (induction plus maintenance). To assess PFS for the entire period in PARAMOUNT, PFS for the induction period was combined with PFS for the randomization period.

The secondary endpoints assessed in addition to the safety profile were OS, disease control rate (DCR), and overall response rate (ORR) in study JMII \[[@b13-crt-2013-266]\], and in study S110 \[[@b12-crt-2013-266]\], and ORR and OS in PARAMOUNT \[[@b10-crt-2013-266],[@b11-crt-2013-266]\].

To assess the safety of maintenance therapy, two types of toxicities were evaluated: adverse events (AEs) with new onset or that deteriorated during the entire treatment period (induction plus maintenance) for patients who received the induction therapy, and AEs with new onset or that deteriorated during maintenance therapy for patients who received maintenance therapy.

5. Statistical methods
----------------------

Detailed statistical methods for all three studies were reported previously \[[@b10-crt-2013-266],[@b12-crt-2013-266],[@b13-crt-2013-266]\]. Data from the investigational treatment arm of each study were used for this review: pemetrexed-cisplatin followed by pemetrexed (PC/P) arm in S110, pemetrexed plus carboplatin arm in JMII, and pemetrexed plus BSC maintenance arm in PARAMOUNT. For JMII and S110, only nonsquamous NSCLC patients were included in efficacy analyses, while all patients were included in safety analyses because the safety profile has not been shown to differ by histology. PARAMOUNT only enrolled nonsquamous patients and hence all results are for nonsquamous patients only.

Results
=======

1. Baseline demographics and treatment
--------------------------------------

[Table 3](#t3-crt-2013-266){ref-type="table"} shows the baseline demographic and disease characteristics of patients who received pemetrexed continuation maintenance therapy in the three studies. The majority of patients in study S110 were never-smokers, whereas the majority of patients in studies JMII and PARAMOUNT were past or current smokers. For the purpose of this analysis, only nonsquamous NSCLC patients (59 patients; 32 in pemetrexed-cisplatin followed by gefitinib \[PC/G\] and 27 in PC/P) were considered for efficacy analyses from study S110; all study S110 patients were included in safety analyses as there has been no evidence to date that toxicity varies by histology. *EGFR* mutation status, which was tested only in study JMII, is shown in [Table 3](#t3-crt-2013-266){ref-type="table"}.

2. Dose administration of pemetrexed maintenance therapy
--------------------------------------------------------

The median number of cycles (range) in patients who received at least one cycle of pemetrexed treatment during the maintenance period in the three studies was as follows: study JMII (n=60), 4 (1, 14); study S110 (n=24), 4 (1, 10); and PARAMOUNT (n=333), 4 (1, 19).

3. Efficacy
-----------

PFS curves for pemetrexed continuation maintenance therapy post-induction are presented in [Fig. 1](#f1-crt-2013-266){ref-type="fig"}. The median PFS during the maintenance period in studies JMII, S110, and PARAMOUNT was 3.9 months (95% confidence interval \[CI\], 3.2 to 5.2 months), 4.04 months (95% CI, 3.22 to 5.29 months), and 4.1 months (95% CI, 3.2 to 4.6 months), respectively ([Table 4](#t4-crt-2013-266){ref-type="table"}). The median PFS during the entire period (induction plus maintenance) in studies JMII, S110, and PARAMOUNT was 5.7 months (95% CI, 4.4 to 7.3 months), 6.83 months (95% CI, 5.78 to 7.98 months), and 6.9 months (95% CI, 6.2 to 7.5 months), respectively ([Table 4](#t4-crt-2013-266){ref-type="table"}).

In study JMII, the median OS during the entire period was 20.2 months (95% CI, 16.7 to not available). In study S110, the median OS could not be estimated due to a high censoring rate (72.9%); however, the 1-year survival rate from randomization at the start of induction therapy was 96.3% (95% CI, 76.5% to 99.5%). In PARAMOUNT, the median OS during the pemetrexed continuation maintenance period was 13.9 months (95% CI, 12.8 to 16.0 months), and the 1-year survival rate from randomization at the start of maintenance therapy was 58.0% (95% CI, 53.0% to 63.0%) \[[@b11-crt-2013-266]\].

The individual response rates during the induction period for JMII and S110 are reported in [Table 5](#t5-crt-2013-266){ref-type="table"}. The DCR for the entire period was 74.5% (95% CI, 65.1% to 82.5%) and 81.5% (95% CI, 61.9% to 93.7%), and the ORR was 35.8% and 37%, in studies JMII and S110, respectively ([Table 5](#t5-crt-2013-266){ref-type="table"}). Individual response rates and DCRs were not available for PARAMOUNT during the entire treatment period due to its unique study design. During the maintenance period, there was 44% complete/partial response, 53% stable disease, and 0.3% progressive disease.

4. Safety
---------

AEs possibly related to study drug with grade ≥ 3 severity are reported by treatment period in [Table 6](#t6-crt-2013-266){ref-type="table"}. The incidence of hematologic AEs was higher than the incidence of non-hematologic and non-laboratory AEs in all three of the studies. Treatment-emergent or worsening AEs during the maintenance period were rare in studies JMII and S110. The most common non-laboratory AEs reported in all three of the studies were fatigue, nausea, and anorexia. The incidence of nausea and vomiting was also frequent during the induction period in studies JMII and S110 ([Table 6](#t6-crt-2013-266){ref-type="table"}).

5. Post-discontinuation anti-cancer therapy
-------------------------------------------

A summary of post-discontinuation anti-cancer therapy for all three studies is reported in [Table 7](#t7-crt-2013-266){ref-type="table"}. There was a trend for higher use of post-discontinuation anti-cancer therapy in EA patients. Among the types of treatments, the use of docetaxel as post-discontinuation anti-cancer therapy was numerically higher compared with any other individual chemotherapy among all three of the studies. Also, use of the targeted therapies erlotinib and gefitinib was relatively high in all three of the studies.

Discussion
==========

Our findings show that median PFS from the start of pemetrexed continuation maintenance therapy in two separate studies that enrolled Japanese, Chinese, and Korean patients was consistent with the median PFS observed in the PARAMOUNT study, which enrolled primarily Caucasian patients. Toxicity and safety results were consistent with those previously reported for PARAMOUNT, indicating that pemetrexed continuation maintenance therapy is well tolerated in EA patients with advanced, nonsquamous NSCLC.

In a follow-up of the PARAMOUNT study, it was reported that pemetrexed continuation maintenance therapy was well tolerated, which corresponded to known pemetrexed toxicities, and that resource use was low \[[@b14-crt-2013-266]\]. Studies JMII and S110 comprised different EA populations, study designs, and treatment regimens. Nonetheless, the additional data in the current analysis indicates consistent patient outcomes across clinical trials of pemetrexed continuation maintenance therapy. This additional data supports the findings of the PARAMOUNT study, and is consistent with another randomized phase II study, in which pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced nonsquamous NSCLC \[[@b15-crt-2013-266]\]. Collectively, these data indicate that pemetrexed maintenance therapy is efficacious among different ethnicities.

The results of this analysis are supported by a recent study, in which continuation maintenance therapy with pemetrexed and switch maintenance therapy with docetaxel were compared in patients with advanced nonsquamous NSCLC who did not experience disease progression after initial therapy with carboplatin and pemetrexed \[[@b16-crt-2013-266]\]. In that study, Karayama et al. \[[@b16-crt-2013-266]\] concluded that pemetrexed continuation maintenance therapy may be an effective treatment option for patients who have achieved disease control after induction therapy as switch maintenance with docetaxel was associated with both increased incidence of severe hematologic AEs and poor survival without toxicity.

A limitation of this analysis is that a comprehensive comparison of the AEs among the three studies could not be performed, since the AEs were defined differently in each study. The high incidence of hematologic toxicities in study JMII is probably due in part to weekly monitoring of laboratory measurements, whereas laboratory measurements were planned before day 1 of each cycle in the other two studies. The high incidence of hematologic toxicities in study JMII may also be due to the use of a different induction platinum regimen (i.e., carboplatin). The safety profile of pemetrexed in studies S110 and JMII was consistent with the safety profile of pemetrexed reported previously \[[@b8-crt-2013-266],[@b9-crt-2013-266]\]. There were no noteworthy differences observed in the safety profile between the two EA trials and PARAMOUNT. Another limitation of this analysis is that limited data were available for EA patients treated with pemetrexed continuation maintenance therapy, since studies S110 and JMII enrolled fewer patients than PARAMOUNT. Also, the eligibility criteria, choice of platinum in the induction therapy, and study designs of the three studies were different, which prevented statistical comparison of data among the three studies.

Efficacy data from the three studies provide an insight on the expected outcomes for pemetrexed continuation maintenance therapy in EA patients with advanced nonsquamous NSCLC. Further studies on pemetrexed continuation maintenance therapy in EA patients are justified. To further establish the role of pemetrexed continuation maintenance as a new treatment paradigm in the global population, data from clinical trials, in addition to data from real-world clinical practice, are needed. These efforts may expand our insight on the role of pemetrexed continuation maintenance therapy in developing targeted treatment strategies for advanced nonsquamous NSCLC.

Conclusion
==========

This analysis adds a moderate amount of data on EA patients for continuation maintenance with pemetrexed to complement the data from PARAMOUNT. The median PFS from the start of maintenance therapy in two separate phase II studies, JMII and S110, which collectively enrolled Japanese, Chinese, Taiwanese, and Korean patients, was consistent with the median PFS observed in PARAMOUNT, which enrolled primarily Caucasian patients. These results suggest that EA patients may benefit from pemetrexed continuation maintenance therapy to a similar degree that Caucasian patients benefit. Toxicity and safety results in studies JMII and S110 were consistent with those previously reported in PARAMOUNT, indicating that pemetrexed is a well-tolerated maintenance treatment in EA patients with advanced nonsquamous NSCLC. Continuation maintenance with pemetrexed is an effective and tolerable treatment for patients with chemonaïve advanced nonsquamous NSCLC.
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###### 

Patients and methods

                                                                                        JMII                                                                                                                               S110                                                                                                                                                                                                  PARAMOUNT
  ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  Study design                                                                          Multicenter, open-label, single-arm post-marketing clinical trial                                                                  Phase II, multicenter, randomized, controlled, open-label study                                                                                                                                       Global, phase III, multicenter, randomized, double-blind, placebo-controlled study
  Histology of patient population                                                                                                                                                                                                                                                                                                                                                                                                
   Original analysis                                                                    NS NSCLC                                                                                                                           SQ and NS NSCLC                                                                                                                                                                                       NS NSCLC
   Analysis for this review                                                             NS NSCLC                                                                                                                           NS NSCLC                                                                                                                                                                                              NS NSCLC
  Induction therapy                                                                     Pemetrexed 500 mg/m^2^ and carboplatin                                                                                             Pemetrexed 500 mg/m^2^ and cisplatin 75 mg/^2^ every 21 days for 4 cycles                                                                                                                             Pemetrexed 500 mg/m^2^ and cisplatin 75 mg/m^2^ every 21 days for 4 cycles
                                                                                         AUC=6 every 21 days for 4 cycles                                                                                                                                                                                                                                                                                                        
   No. of patients enrolled/entered                                                     111                                                                                                                                86[^a)^](#tfn2-crt-2013-266){ref-type="table-fn"}                                                                                                                                                     1,022
   No. of patients treated with induction therapy                                       109                                                                                                                                70[^a)^](#tfn2-crt-2013-266){ref-type="table-fn"}                                                                                                                                                     939
   No. of patients with NS disease                                                      109                                                                                                                                59                                                                                                                                                                                                    939
  Randomization                                                                         No                                                                                                                                 Yes (prior to induction therapy)                                                                                                                                                                      Yes (prior to maintenance therapy)
   Maintenance therapy                                                                  Pemetrexed 500 mg/m^2^every 21 days until PD                                                                                       Optional cisplatin 75 mg/m^2^ for first 2 cycles and pemetrexed 500 mg/m^2^ every 21 days until PD/death/unacceptable toxicity                                                                        Pemetrexed 500 mg/m^2^ and BSC every 21 days until PD/unacceptable toxicity/decision of the patient or physician
                                                                                                                                                                                                                                                                                                                                                                                                                                 
    No. of randomized patients to pemetrexed/treated with pemetrexed maintenance        60                                                                                                                                 24[^b)^](#tfn3-crt-2013-266){ref-type="table-fn"}                                                                                                                                                     359
    No. of patients with NS disease                                                     60                                                                                                                                 22                                                                                                                                                                                                    359
   Comparator                                                                           NA                                                                                                                                 Gefitinib 250 mg orally every day until PD/death/unacceptable toxicity                                                                                                                                Placebo and BSC every 21 days until PD/unacceptable toxicity/decision of the patient or physician
   No. of randomized patients to comparator group                                       NA                                                                                                                                 25[^c)^](#tfn4-crt-2013-266){ref-type="table-fn"}                                                                                                                                                     180
  Efficacy endpoints                                                                                                                                                                                                                                                                                                                                                                                                             
   Primary                                                                              PFS from enrollment date to PD or death (induction plus maintenance)                                                               PFS from enrollment date to PD or death (induction plus maintenance); however, for the primary endpoint analysis, it was evaluated for the maintenance period only using a time-dependent Cox model   PFS from randomization date to PD or death (maintenance)
   Secondary                                                                            OS, DCR, ORR, response rate in induction and DCR in maintenance                                                                    ORR, DoR, OS                                                                                                                                                                                          OS, ORR
  Baseline for efficacy and safety assessment                                           Enrollment                                                                                                                         Randomization                                                                                                                                                                                         Randomization
  Efficacy analysis set                                                                 Treated patients with no significant protocol violation                                                                            Randomized and treated patients                                                                                                                                                                       Randomized patients
  Safety analysis set                                                                   Patients who received at least one dose of pemetrexed and carboplatin induction therapy                                            Randomized and treated patients                                                                                                                                                                       Randomized patients
  Adverse events assessment                                                             AEs which onset newly or worsened in the entire treatment (induction+maintenance) in patients who received induction therapy       AEs which onset newly in maintenance or worsened from baseline and induction period                                                                                                                   AEs which onset newly or worsened in the entire treatment (induction+maintenance) in patients who received the induction therapy
  AEs which onset newly in maintenance or worsened from baseline and induction period   AEs which onset newly or worsened in the entire treatment (induction+maintenance) in patients who received the induction therapy   AEs which onset newly in maintenance or worsened from baseline and induction period                                                                                                                   
  PFS assessed in this manuscript                                                       PFS for entire period-PFS for induction therapy period                                                                             PFS for maintenance period                                                                                                                                                                            PFS for only maintenance therapy

NS, nonsquamous; NSCLC, non-small cell lung cancer; SQ, squamous; AUC, area under curve; PD, progressive disease; BSC, best supportive care; NA, not applicable; PFS, progression-free survival; OS, overall survival; DCR, disease control rate; ORR, objective response rate; DoR, duration of response; AE, adverse event; PC/G, pemetrexed+cisplatin followed by gefitinib; PC/P, pemetrexed+cisplatin followed by pemetrexed.

Of 73 NSCLC patients who were enrolled and randomized, 70 patients received induction treatment, of which 59 patients (32 in the PC/G arm and 27 in the PC/P arm) had NS NSCLC,

Of 24 NSCLC patients in the pemetrexed maintenance arm in study S110, 22 patients had NS NSCLC,

Of 25 NSCLC patients in the gefitinib maintenance arm in study S110, 23 patients had NS NSCLC.

###### 

Key eligibility criteria

                                                                    JMII                                                           S110                                                                             PARAMOUNT
  ----------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Age                                                               ≥ 20 yr                                                        ≥ 18 yr                                                                          ≥ 18 yr
  ECOG PS                                                           0-1                                                            0-1                                                                              0-1
  Stage                                                             IIIB/IV, post-operative recurrent disease                      IIIB/IV                                                                          IIIB/IV
  Histology                                                         NS NSCLC                                                       SQ and NS NSCLC                                                                  NS NSCLC
  Smoking status                                                    NA                                                             Never-smoker[^a)^](#tfn6-crt-2013-266){ref-type="table-fn"}                      NA
  *EGFR* mutation status                                            NA                                                             Unknown                                                                          NA
  CNS metastasis                                                    Stable or treated brain metastasis allowed                     Stable or treated brain metastasis allowed                                       Stable or treated brain metastasis allowed
  Prior treatment history                                           Chemonaïve                                                     Chemonaïve                                                                       Chemonaïve
  Adjuvant excluded                                                 Radiotherapy \< 25% of the bone marrow                         Adjuvant excluded                                                                
  Radiotherapy \< 25% of the bone marrow                                                                                           Radiotherapy \< 25% of the bone marrow                                           
  Adequate organ function                                           Bone marrow reserve, renal, hepatic                            Bone marrow reserve, renal, hepatic                                              Bone marrow reserve, renal, hepatic
  Weight loss                                                       NA                                                             ≤ 10% within 6 weeks prior to study entry                                        NA
  Measurable lesions                                                Measurable lesions meeting RECIST ver. 1.0 criteria            At least 1 unidimensionally measurable lesion meeting RECIST ver. 1.0 criteria   At least 1 unidimensionally measurable lesion meeting RECIST ver. 1.0 criteria
  Criteria for randomization and/or receiving maintenance therapy   Evidence of CR, PR or SD after 4 cycles of induction therapy   Four cycles of induction therapy                                                 Documented radiographic evidence of a tumor response of CR, PR, or SD after 4 cycles of induction therapy
  Life expectancy                                                   At least 12 weeks                                              Less than 12 weeks                                                               At least 12 weeks

ECOG PS, Eastern Cooperative Oncology Group performance status; NS, nonsquamous; NSCLC, non-small cell lung cancer; SQ, squamous; NA, not applicable/not available; *EGFR*, epidermal growth factor receptor; CNS, central nervous system; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease.

Defined as having smoked \< 100 cigarettes during his/her life.

###### 

Baseline characteristics[^a)^](#tfn8-crt-2013-266){ref-type="table-fn"}

  Variable                  JMII PCb/P (n=109)                                          S110 PC/P ind+mnt (n=27)   S110 PC/P mnt (n=22)   PARAMOUNT P+BSC mnt (n=359)
  ------------------------- ----------------------------------------------------------- -------------------------- ---------------------- -----------------------------
  Age (yr)                                                                                                                                
   Median (range)           63 (38-78)                                                  57.0 (29-75)               54.5 (29-74)           61 (32-79)
  Gender                                                                                                                                  
   Female                   40 (36.7)                                                   22 (81.5)                  17 (77.3)              158 (44)
   Male                     69 (63.3)                                                   5 (18.5)                   5 (22.7)               201 (56)
  Ethnic origin                                                                                                                           
   Asian                    \-                                                          \-                         \-                     16 (4)
    Japan                   109 (100)                                                   \-                         \-                     \-
    China                   \-                                                          13 (48.1)                  12 (54.5)              \-
    Korea                   \-                                                          6 (22.2)                   5 (22.7)               \-
    Taiwan                  \-                                                          8 (29.6)                   5 (22.7)               \-
   Caucasian                \-                                                          \-                         \-                     339 (94)
   African                  \-                                                          \-                         \-                     4 (1)
  Stage of disease                                                                                                                        
   Stage IIIB               33 (30.3)                                                   3(11.1)                    3 (13.6)               31 (9)
   Stage IV                 72 (66.1)                                                   24 (88.9)                  19 (86.4)              328 (91)
   Recurrence               4 (3.7)                                                     \-                         \-                     \-
  ECOG performance status                                                                                                                 
   0                        37 (33.9)                                                   8 (29.6)                   8 (36.4)               115 (32)
   1                        72 (66.1)                                                   19 (70.4)                  14 (63.6)              243 (68)
   2-3                      \-                                                          \-                         \-                     1 ( \< 1)
  Histological subtypes                                                                                                                   
   Adenocarcinoma           106 (97.2)[^b)^](#tfn9-crt-2013-266){ref-type="table-fn"}   24 (88.9)                  21 (95.5)              304 (85)
   Large cell               3 (2.8)                                                     1 (3.7)                    \-                     24 (7)
   Bronchoalveolar          \-                                                          \-                         \-                     6 (2)
   Other                    \-                                                          2 (7.4)                    1 (4.5)                25 (7)
  Smoking                                                                                                                                 
   Ever                     76 (69.7)                                                   2 (7.4)                    1 (4.5)                275 (77)
   Never                    33 (30.3)                                                   25 (92.6)                  21 (95.5)              82 (23)
   Unknown                  0                                                           0                          \-                     2 ( \< 1)
  *EGFR* mutation status                                                                                                                  
   Positive                 24 (22.0)                                                   \-                         \-                     \-
   Negative                 63 (57.8)                                                   \-                         \-                     \-
   Unknown                  3 (2.8)                                                     \-                         \-                     \-
   Not done                 19 (17.4)                                                   \-                         \-                     \-

Values are presented as number (%). PCb/P, pemetrexed+carboplatin followed by pemetrexed; PC/P, pemetrexed+cisplatin followed by pemetrexed; ind, induction; mnt, maintenance; P+BSC, pemetrexed+best supportive care; ECOG, Eastern Cooperative Oncology Group; *EGFR*, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.

Baseline characteristics prior to induction for studies JMII and S110, but prior to maintenance for PARAMOUNT randomization,

Includes 1 patient reclassified as having squamous NSCLC after study entry and examination of *EGFR* gene type was not done.

###### 

Summary of efficacy parameters for patients with nonsquamous disease

  Efficacy parameter                                                                  JMII PCb/P                                            S110 PC/P                                            PARAMOUNT P+BSC mnt
  ----------------------------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------
  Induction regimen                                                                   Carboplatin+pemetrexed                                Cisplatin+pemetrexed                                 Cisplatin+pemetrexed
  Induction sample size                                                               106                                                   27                                                   939
  Maintenance sample size                                                             60 (56.6%)                                            22 (81.5%)                                           359 (66.6%)[^a)^](#tfn11-crt-2013-266){ref-type="table-fn"}
  Efficacy during maintenance therapy                                                                                                                                                            
   Maintenance regimen                                                                Pemetrexed                                            Pemetrexed                                           Pemetrexed
   No.                                                                                60                                                    22                                                   359
   Median PFS (95% CI, mo)                                                            3.9 (3.2-5.2)                                         4.04 (3.22-5.29)                                     4.1 (3.2-4.6)
  Efficacy during induction+maintenance period                                                                                                                                                   
   No.                                                                                106[^b)^](#tfn12-crt-2013-266){ref-type="table-fn"}   27                                                   359[^a)^](#tfn11-crt-2013-266){ref-type="table-fn"}
   Median PFS (95% CI, mo)                                                            5.7 (4.4-7.3)                                         6.83 (5.78-7.98)                                     6.9 (6.2-7.5)
   Median OS (95% CI, mo)[^c)^](#tfn13-crt-2013-266){ref-type="table-fn"}             20.2 (16.7-NA)                                        NR[^d)^](#tfn14-crt-2013-266){ref-type="table-fn"}   13.9 (12.8-16.0)
   1-Year survival rate (95% CI, %)[^c)^](#tfn13-crt-2013-266){ref-type="table-fn"}   70.0 (60.4-77.8)                                      96.3 (76.5-99.5)                                     58 (53.0-63.0)
   2-Year survival rate (95% CI, %)[^c)^](#tfn13-crt-2013-266){ref-type="table-fn"}   42.5 (32.8-51.8)                                      78.0 (54.7-90.2)                                     32 (27.0-37.0)
  Subgroup analysis                                                                                                                                                                              
   Median PFS (95% CI, mo), *EGFR* mutation-positive patients                         5.7 (5.2-7.2)                                         NA[^e)^](#tfn15-crt-2013-266){ref-type="table-fn"}   NA[^e)^](#tfn15-crt-2013-266){ref-type="table-fn"}
   Median PFS (95% CI, mo), *EGFR* mutation-negative patients                         6.9 (4.3-7.8)                                         NA[^e)^](#tfn15-crt-2013-266){ref-type="table-fn"}   NA[^e)^](#tfn15-crt-2013-266){ref-type="table-fn"}
                                                                                                                                                                                                 

PCb/P, pemetrexed+carboplatin followed by pemetrexed; PC/P, pemetrexed+cisplatin followed by pemetrexed; P+BSC mnt, pemetrexed+best supportive care maintenance; PFS, progression-free survival; CI, confidence interval; OS, overall survival; NA, not available; NR, not reached; *EGFR*, epidermal growth factor receptor.

In PARAMOUNT, 939 patients were enrolled into the induction phase, and 539 patients (57.4%) (pemetrexed \[n=359\], placebo \[n=180\]) were randomized,

Efficacy assessment was performed on per-protocol set, which consisted of 106 treated patients without major protocol violations as reported in the JMII manuscript,

In PARAMOUNT, median OS, 1-year and 2-year survival rates are reported for the maintenance period but for the induction+maintenance period for S110 and JMII,

There were insufficient events to calculate median OS in study S110 due to censoring (72.9% cases were censored),

The *EGFR* mutation analysis was not performed in studies S110 and PARAMOUNT.

###### 

Response rates and disease control rates for entire treatment period and during induction period for patients with nonsquamous disease

                                                                          Entire treatment period   Induction period                      
  ----------------------------------------------------------------------- ------------------------- ------------------ ------------------ ------------------
  Best overall response[^a)^](#tfn17-crt-2013-266){ref-type="table-fn"}                                                                   
   Complete response                                                      0                         0                  0                  0
   Partial response                                                       38 (35.8)                 10 (37.0)          42 (39.6)          5 (18.5)
   Stable disease                                                         41 (38.7)                 12 (44.4)          45 (42.5)          17 (63.0)
   Progressive disease                                                    20 (18.9)                 3 (11.1)           15 (14.2)          2 (7.4)
   Unknown                                                                7 (6.6)                   1 (3.7)            4 (3.8)            2 (7.4)
   Early death from toxicity                                              NA                        1 (3.7)            0                  1 (3.7)
  Disease control rate (CR+PR+SD)                                         74.5 (65.1-82.5)          81.5 (61.9-93.7)   82.1 (73.4-88.8)   81.5 (61.9-93.7)
  Overall response rate (CR+PR)                                           35.8 (26.8-45.7)          37.0 (NA)          39.6 (30.3-49.6)   18.5 (6.3-38.1)

Values are presented as number (%) or percent (95% CI). PC/P, pemetrexed+cisplatin followed by pemetrexed; NA, not available/not applicable; CR, complete response; PR, partial response; SD, stable disease; CI, confidence interval.

The best overall response data for the entire treatment period were not captured in PARAMOUNT due to the unique study design.

###### 

Adverse events grade ≥ 3 and possibly related to study drug across all studies during induction and/or pemetrexed maintenance period

  Grade ≥ 3 AE                              JMII[^a)^](#tfn19-crt-2013-266){ref-type="table-fn"}   S110[^b)^](#tfn20-crt-2013-266){ref-type="table-fn"}   PARAMOUNT^[c)](#tfn21-crt-2013-266){ref-type="table-fn"},[d)](#tfn22-crt-2013-266){ref-type="table-fn"},[e)](#tfn23-crt-2013-266){ref-type="table-fn"}^              
  ----------------------------------------- ------------------------------------------------------ ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ----------
  Patients with ≥ 1                         \-                                                     \-                                                     \-                                                                                                                                                        \-         33 (9)
  laboratory AE                                                                                                                                                                                                                                                                                                                
    Hematologic AEs                         \-                                                     \-                                                     6 (19.4)                                                                                                                                                  3 (12.5)   \-
     Anemia                                 34 (31.2)                                              1 (1.7)                                                1 (3.2)                                                                                                                                                   1 (4.2)    16 (4)
     Neutropenia                            62 (56.9)                                              3 (5.0)                                                5 (16.1)                                                                                                                                                  2 (8.3)    13 (4)
     Leukopenia                             24 (22.0)                                              1 (1.7)                                                1                                                                                                                                                         1          6 (2)
     Thrombocytopenia                       45 (41.3)                                              0                                                      0                                                                                                                                                         0          4 (1)
   Non-hematologic AEs                                                                                                                                                                                                                                                                                                         
    Alanine aminotransferase                7 (6.4)                                                2 (3.3)                                                1 (3.2)                                                                                                                                                   0          1 (\<1)
    Aspartate aminotransferase              2 (1.8)                                                1 (1.7)                                                0                                                                                                                                                         0          0
    Hypokalemia                             0                                                      0                                                      1 (3.2)                                                                                                                                                   0          0
    Hyponatremia                            0                                                      0                                                      1 (3.2)                                                                                                                                                   0          0
    Metabolic/laboratory, other             0                                                      0                                                      2 (6.5)                                                                                                                                                   0          0
  Patients with ≥ 1 non-laboratory AE       \-                                                     \-                                                     \-                                                                                                                                                        \-         32 (9)
    Fatigue (asthenia, lethargy, malaise)   2 (1.8)                                                                                                       2 (6.5)                                                                                                                                                   2 (6.5)    15 (4)
    Nausea                                  1 (0.9)                                                                                                       3 (9.7)                                                                                                                                                   0          1 (\< 1)
    Vomiting                                3 (2.8)                                                                                                       4 (12.9)                                                                                                                                                  0          0
    Mucositis or stomatitis                 0                                                                                                             0                                                                                                                                                         0          1 (\< 1)
    Anorexia/appetite loss                  6 (5.5)                                                                                                       1 (3.2)                                                                                                                                                   0          1 (\< 1)
    Pain, any event                         0                                                                                                             0                                                                                                                                                         0          3 (\< 1)
    Infection                               0                                                                                                             0                                                                                                                                                         0          4 (1)
    Neuropathy: sensory                     0                                                                                                             0                                                                                                                                                         0          1 (\< 1)
    Dyspnea                                 0                                                                                                             2 (6.5)                                                                                                                                                   1 (4.2)    0
    Rash                                    1 (0.9)                                                                                                       0                                                                                                                                                         0          0
    Pneumonitis                             0                                                                                                             1 (3.2)                                                                                                                                                   0          0
    Fever                                   1 (0.9)                                                                                                       0                                                                                                                                                         0          0

Values are presented as number (%). PCb/P, pemetrexed+carboplatin followed by pemetrexed; PC/P, pemetrexed+cisplatin followed by pemetrexed (10 patients also received optional cisplatin); AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; NCI-CTCAE, National Cancer Institute-Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; P, pemetrexed; TEAEs, treatment-emergent adverse events.

Toxicities in study JMII were TEAEs based on MedDRA ver. 14.1 and NCI-CTCAE ver. 3.0 preferred terms,

Toxicities in study S110 were based on NCI-CTCAE ver. 3.0; 4 patients had squamous NSCLC on PC/P induction+P maintenance and 2 patients had squamous NSCLC on PC/P maintenance period. There has been no evidence to date that toxicity varies by histology,

Toxicities in PARAMOUNT were TEAEs based on NCI-CTCAE ver. 3.0,

Among possibly drug-related AEs during the maintenance treatment period, no laboratory AEs of grade 5 (deaths) and 2 non-laboratory AEs of grade 5 (deaths) were recorded: 1 patient died in the pemetrexed group (pneumonia) and 1 patient died in the placebo group (sudden death---not otherwise specified),

For PARAMOUNT, the decimals are rounded off to be consistent with the original publication.

###### 

Summary of post-discontinuation anti-cancer therapy in studies JMII, S110, and PARAMOUNT

  Post-study anti-cancer therapy[^a)^](#tfn25-crt-2013-266){ref-type="table-fn"}   JMII        S110[^b)^](#tfn26-crt-2013-266){ref-type="table-fn"}   PARAMOUNT[^c)^](#tfn27-crt-2013-266){ref-type="table-fn"}   
  -------------------------------------------------------------------------------- ----------- ------------------------------------------------------ ----------------------------------------------------------- ----------
  Any post-study anti-cancer therapy                                               86 (78.9)   50 (83.3)                                              25 (80.6)                                                   231 (64)
   Surgery                                                                         0           0                                                      1 (3.2)                                                     \-
   Radiotherapy                                                                    9 (8.3)     3 (2.8)                                                13 (41.9)                                                   \-
  Chemotherapy (≥ 1 line)                                                          \-          \-                                                     18 (58.1)                                                   \-
   Pemetrexed                                                                      11 (10.1)   4 (6.7)                                                0                                                           7 (2)
   Docetaxel                                                                       43 (39.4)   24 (40.0)                                              10 (32.3)                                                   116 (32)
   Other                                                                           59 (54.1)   32 (53.3)                                              11 (35.5)                                                   96 (27)
  Biological (targeted therapy)                                                    34 (31.2)   19 (31.7)                                              18 (58.1)                                                   \-
   Erlotinib                                                                       19 (17.4)   11 (18.3)                                              5 (16.1)                                                    142 (40)
   Gefitinib                                                                       16 (14.7)   8 (13.3)                                               14 (45.2)                                                   3 (0.8)
   Vandetanib                                                                      0           0                                                      3 (9.7)                                                     0
   BIBW2992                                                                        0           0                                                      4 (12.9)                                                    0
   Sorafenib                                                                       0           0                                                      0                                                           0
   Cetuximab                                                                       0           0                                                      1 (3.2)                                                     0
   Bevacizumab                                                                     8 (7.3)     4 (6.7)                                                1 (3.2)                                                     6 (2)
   Afatinib                                                                        0           0                                                      0                                                           2 (0.6)
  Immunological                                                                    0           0                                                      1 (3.2)                                                     0
  Investigational drug                                                             9 (8.3)     8 (13.3)                                               0                                                           20 (6)
  Placebo                                                                          0           0                                                      0                                                           4 (1)

Values are presented as number (%). PC/P, pemetrexed+cisplatin followed by pemetrexed; NSCLC, non-small cell lung cancer.

Patients may have received ≥ 1 post-study anti-cancer therapy,

In study S110, post-discontinuation therapy details were reported for all NSCLC patients,

For PARAMOUNT, the decimals are rounded off to be consistent with the original publication.
